Nuacht

MyChesCo on MSN1 uair an chloig
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer
Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...
Clinical Trials Arena on MSN6 lá
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...
AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer
AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...
Fierce Pharma7 lá
AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial
Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...
The Pharma Letter7 lá
AstraZeneca and Daiichi push Enhertu into earlier breast cancer use
UK-based pharma major AstraZeneca and its Japanese partner Daiichi Sankyo are moving to expand the reach of their blockbuster ...
pharmaphorum7 lá
New data could move Enhertu into early breast cancer
AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...
Health And Pharma8 lá
Enhertu Plus THP Outperforms Standard Chemotherapy in High-Risk, Early-Stage HER2+ Breast Cancer
The Phase III DESTINY-Breast11 trial showed Enhertu followed by THP significantly improved pathologic complete response (pCR) ...
AstraZeneca receives 'positive high-level results' results from Enhertu trial
Drugmaker AstraZeneca revealed on Wednesday that it had received "positive high-level results" from a Phase III trial on its ...
Applied Clinical Trials Online7 lá
DESTINY-Breast11 Trial Shows Enhertu Plus THP Significantly Improves Response Rates in High-Risk HER2-Positive Early Breast Cancer
Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...
PharmiWeb7 lá
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...
Cbonds8 lá
AstraZeneca: Enhertu improved pCR in early-stage breast cancer
— We have everything you need: full data on over 800 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...